SecBot SecBot
6-K ·Filed Oct 30, 2026

EVAX

Evaxion A/S
NEUTRAL
Impact 2/10
Horizonweeks Processed17d 20h ago SEC0001171843-26-006992
Notable filing: 6-K
Actionable Insight • Neutral

The award is a reputational milestone but does not alter the company's clinical or financial trajectory. Monitor upcoming clinical data readouts and capital needs for the clinical-stage pipeline.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$2.93
T+0 close · Oct 30, 2026 · via day close
Latest settled
+2.39%
T+5 · $3.00 · next T+20 in 13d
Vs SPY
+5.09%
α at T+5
Latest observation
−2.88%
T+11 · FF3 residual α
  1. T+0 · Oct 30 $2.93entry
  2. T+1 · 15d ago −0.34%α +0.14% · $2.92
  3. T+5 · 11d ago +2.39%α +5.09% · $3.00
  4. T+11 · todayOpen
  5. T+20 · in 13d Pending
  6. T+60 · in 2mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion announced it received the 2026 International Prix Galien Award for its AI-Immunology platform as best digital health solution. This is a prestigious recognition but does not include any financial data, revenue, or changes to the company's pipeline or financial outlook.

Key Facts

  • Evaxion awarded the 2026 International Prix Galien Award for AI-Immunology as best digital health solution.
  • First time a Danish company has won this international award.
  • The award is presented every two years and is often regarded as the equivalent of the Nobel Prize in biopharmaceutical research.
  • Evaxion previously won the Prix Galien UK Award in June 2026 and the Nordic/European/Middle Eastern award in December 2025.
  • No financial results, guidance, or material business changes were disclosed in this filing.

Financial Impact

No financial impact stated; the filing contains no revenue, earnings, or financial data.

Risk Factors

  • No financial information provided; the company remains a clinical-stage biotech with no approved products and likely ongoing capital requirements.
  • Forward-looking statements highlight risks including need for additional capital and dependence on clinical trial success.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-006992
Document: f6k_103026.htm0001171843-26-006992
Document: 0001171843-26-006992-index-headers.html0001171843-26-006992
Document: 0001171843-26-006992-index.html0001171843-26-006992
Document: 0001171843-26-006992.txt0001171843-26-006992
Earnings Context (Synthetic; results releases only)0001171843-26-006992

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Viewing Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 39m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 30, 2026